相关实验视频

Updated: Jun 1, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

用尼克酶向BRCA1缺乏的PARP抑制剂耐药细胞,揭示了尼克切除是癌症脆弱性的原因

Jenna M Whalen¹, Jillian Earley¹, Christi Wisniewski¹

¹Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.

|January 21, 2025

概括

具有BRCA基因突变的瘤对PARP1抑制剂敏感. 在BRCA1缺乏细胞中,53BP1-Shieldin复合体的丧失增加了对DNA切割的敏感性,从而提供了新的治疗策略.

科学领域:

遗传学是一个遗传学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

缺少BRCA1和BRCA2 (BRCA) 基因的瘤对诸如多 (ADP-ribose) 聚合酶1 (PARP1) 抑制剂等对DNA损伤剂的敏感性增加.
在BRCA缺陷癌症中获得对PARP1抑制剂的耐药性是一个重大的临床挑战,需要新的治疗方法.

研究的目的:

研究BRCA1缺乏细胞中对PARP1抑制剂的耐药性机制.
探索针对BRCA缺陷癌症的DNA修复途径的新型治疗策略.

主要方法:

利用CRISPR技术对BRCA1缺陷癌细胞进行遗传查.
评估了DNA末端切除,同源重组,以及对DNAnicks和PARP1抑制剂的敏感性.
研究了53BP1-Shieldin复合体在DNA修复和耐药性的作用.

主要成果:

在BRCA1缺乏细胞中,53BP1-Shieldin复合物的丧失通过增加DNA末端切除来增强同源重组.
这种增强的切除导致对DNA破裂的敏感性增加,通过超切除到单链DNA中导致细胞死亡.
53BP1-Shieldin复合体在限制扩张方面发挥着关键作用,其损失使细胞对敏感.

结论:

针对DNA修复途径,特别是通过调节同源重组和DNA末端切除,可以克服对PARP1抑制剂的耐药性.
53BP1-Shieldin复合体是DNA修复和耐药性的关键调节者,其抑制是一种潜在的治疗策略.
DNA尼克酶显示出作为个性化医学的工具在治疗BRCA缺陷瘤中的承诺,利用对DNA尼克的高度敏感性.

更多相关视频

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

相关概念视频

Base Excision Repair

Base Excision Repair

One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...

Long-patch Base Excision Repair

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:

Restarting Stalled Replication Forks

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Nucleotide Excision Repair

Nucleotide Excision Repair

Proofreading

Proofreading